Abstract:e13556 Background: Immune checkpoint inhibitors (ICI) are used to manage patients with both small cell (SCLC) and non-small cell (NSCLC) lung cancer. However, ICI response rates are often low, and identifying patients that will benefit from ICIs can be challenging. The value of biomarkers used to predict ICI response, such as PD-L1, Combined Positive Score (CPS) or tumor mutational burden (TMB) have been debated. Furthermore, the resources needed to assess these biomarkers may not be available in many centres. Developing more accurate and accessible tools that predict ICI responses could enable a precision medicine approach that improves patient outcomes. This study aimed to use a novel machine-learning (ML) algorithm to predict response to different ICI therapies in patients with lung cancer based on clinically available data. Methods: 334 eligible records were cleaned and reprocessed from textual to categorical data using one hot encoding. Complete datasets were available for 161 patients. Differences in the data distribution were handled using the Synthetic Minority Oversampling Technique. Six ML algorithms were trained, including Linear regression, Support Vector Classifier, XGBoost Classifier, Random Forest, Decision Tree, and Gaussian Naive Bayes Classifier. These algorithms used 80% of the training data, were tested on 20% of validation data and used the Grid Search Cross-Validation technique for hyperparameter optimization. Results: For the 161 patients included in the final analysis, the mean age was 68 years and 48% were female. 9% of patients had SCLC and 80% had NSCLC. Patients receiving Pembrolizumab, Nivolumab and Atezolizumab comprised 62%, 11% and 25%, respectively. The artificial intelligence (AI) algorithm predicted and stratified ICI response better than PD-L1 levels. Of the ML algorithms, XGBoost Classifier predicted response with the most accuracy, 64% (0.61 F1 score). This model found that good performance status (0-1), female gender and adenocarcinoma sub-type predicted response to ICI. On the other hand, M1, N2 staging, male gender, squamous cell carcinoma sub-type and receiving Atezolizumab were predictive of disease progression. Conclusions: This study developed multiple novel ML models to predict responses to ICIs in lung cancer. XGBoost Classifier used clinically available data to show that the type of ICI a patient receives, their histopathology sub-type and their TMN staging impact ICI response. Future work will aim to improve accuracy and predict ICI toxicity by including data from multiple centres, different cancer types and additional clinical variables. [Table: see text]

Prediction of Chemosensitivity in Multiple Primary Cancer Patients Using Machine Learning

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection

Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response

Prediction of Cancer Cell Sensitivity to Natural Products Based on Genomic and Chemical Properties.

[Prediction of cancer drug sensitivity based on genomic feature distribution alignment and drug structure information]

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Improving the prediction of chemotherapeutic sensitivity of tumors in breast cancer via optimizing the selection of candidate genes

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores

Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Predicting Anticancer Drug Responses Using A Dual-Layer Integrated Cell Line-Drug Network Model

Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Anti-cancer Drug Response Prediction Using Neighbor-Based Collaborative Filtering with Global Effect Removal

Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer

Establishment of Chemotherapy Prediction Model Based on Hypoxia-Related Genes for Oral Cancer

Predicting breast cancer drug response using a multiple-layer cell line drug response network model

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials

Predicting cancer immunotherapy response from gut microbiomes using machine learning models